Source: Business Wire From: yahoo.com Positive opinion based on results from largest Phase 3 trial performed to date of a PARP inhibitor in gBRCA-mutated advanced breast cancer Pfizer Inc. (PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase …
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
Source: Checkpoint Therapeutics, Inc From: apnews.com >40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with …
Exercise Proves Beneficial for Breast Cancer Survivors, Yet Again
By: Christina Bennett, MS From: cancernetwork.com A 4-month exercise program reduced the risk of cardiovascular disease among breast cancer survivors who were considered sedentary and overweight or obese, a prospective, randomized, single-center clinical trial (ClinicalTrials.gov identifier: NCT01140282) published in JAMA Oncology showed. These findings are the latest to show the various benefits exercise has for breast cancer patients. For instance, …
CDK4/6 Inhibitors Firmly Established in HR+ Breast Cancer, OS Data Awaited
By: Gina Columbus From: onclive.com The improvement in progression-free survival (PFS) that has been observed with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has led to changes in clinical practice. However, physicians are still awaiting further overall survival (OS) findings that will solidify the use of these agents, said Daphne B. Stewart, MD. Thus far, …
AstraZeneca, Daiichi Sankyo’s $6.9B breast cancer drug partnership bears fruit in less than two months
By: Alaric DeArment From: medcitynews.com The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study. The growing field of antibody-drug conjugates may soon get a new member with positive Phase II data in breast cancer. Anglo-Swedish drugmaker AstraZeneca and Japan-based Daiichi …
Clinical trial helps advance breast cancer research
By: Ken Sury From: wacotrib.com Cindie Young didn’t find a lump in her breast. Neither did a routine mammogram. But she also knew something wasn’t right. She was absolutely correct. Another mammogram and a sonogram found the cancer. Young now is part of a clinical trial overseen by Dr. Carlos Encarnacion with Texas Oncology in Waco that hopes to help …
Immunotherapy for lung cancer: Researchers working to broaden its reach
By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …
Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
Source: Business Wire From: oaoa.com Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast …
Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies
Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone …
Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC
From: scnow.com Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC). Approximately 20% of patients with TNBC have tumors that highly …